Here are the Form 4 insider transactions from Syra Health Corp A (SYRA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SYRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SYRA filings page.
Syra Health Corp CEO Gregory R. Alexander was granted 368,458 performance stock units on August 31, 2026. His reported post-grant position was 368,458 units, tied to 368,458 underlying Class A Common Stock shares. The award provides that 20% of the units vest one year after the grant date; the remainder vest upon achievement of certain company financial metrics.
Syra Health Corp reported that its CEO, Gregory R. Alexander, received grants of 257,920 stock options and 110,537 restricted stock units on January 5, 2026. Twenty percent of each award vests on each December 31 from 2026 through 2030. The options have a $0.09 per-share exercise price and expire January 5, 2036.
Syra Health Corp COO and CFO Priya Prasad received compensation-related awards on August 31, 2026: 86,696 Performance Stock Units, 60,687 stock options, and 26,009 Restricted Stock Units. Those amounts are her reported post-transaction positions in each award. The options have an exercise price of $0.92 per share.
Twenty percent of the Performance Stock Units vest each year after the grant, subject to achievement of certain company financial metrics. Twenty percent of the options and restricted stock units vest on each December 31 from 2026 through 2030.
Syra Health Corp (SYRA) reported that its COO and CFO, Priya Prasad, received equity awards on August 31, 2026. These include 86,696 Performance Stock Units tied to company financial metrics, 60,687 stock options with a $0.92 exercise price, and 26,009 Restricted Stock Units, all relating to Class A common stock.
Twenty percent of the Performance Stock Units vest each year after the grant date subject to achieving specified company financial metrics. Twenty percent of the options and Restricted Stock Units vest on each of December 31, 2027, 2028, 2029, 2030 and 2031; the options and Performance Stock Units expire on August 31, 2036. No Rule 10b5-1 trading plan is reported.
Syra Health Corp reported that CEO Alexander Gregory R. received a grant of 368,458 Performance Stock Units linked to Class A Common Stock. The units carry a zero exercise price and expire on August 11, 2036. According to the vesting terms, 20% of the Performance Stock Units vest one year after the grant date, with the remaining units vesting upon achievement of specified company financial metrics, tying a substantial portion of this award to the company’s future performance.
Syra Health Corp. reported that CEO Gregory R. Alexander received new equity awards. On January 5, 2026, he was granted 110,537 restricted stock units at $0.00 per unit and 257,920 stock options with a $0.09 exercise price.
For both grants, 20% vest one year after the grant date. The remaining 80% vest in equal installments over the following four years on each anniversary of the grant date, aligning his compensation with longer-term company performance.
Syra Health Corp (SYRA) reported a new stock option grant to director Vijayapal R. Reddy. On 11/21/2025, he received stock options with an exercise price of $0.07 per share for 43,348 shares of Class A common stock, expiring on 11/21/2035.
The options were issued under the company’s 2022 Omnibus Equity Incentive Plan. One-third of the options vest on December 31, 2025, with the remaining two-thirds vesting in equal portions on December 31, 2026 and December 31, 2027. After this grant, Reddy beneficially owns 70,926 derivative securities (stock options).
Syra Health Corp (SYRA) reported a new equity award to one of its directors. On 11/21/2025, the director received stock options to acquire 43,348 shares of Class A common stock at an exercise price of $0.07 per share under the company’s 2022 Omnibus Equity Incentive Plan.
One-third of these options vest on December 31, 2025, with the remaining two-thirds vesting in equal portions on December 31, 2026 and December 31, 2027. Following this grant, the director beneficially owns 77,821 derivative securities directly, aligning compensation with the company’s future share performance.
Syra Health Corp (SYRA) reported that director Avutu S. Reddy received a new stock option grant. On 11/21/2025, Reddy acquired options to purchase 43,348 shares of Class A common stock at an exercise price of $0.07 per share, expiring on 11/21/2035.
The options were issued under the company’s 2022 Omnibus Equity Incentive Plan. One-third of the options vest on December 31, 2025, with the remaining two-thirds vesting in equal parts on December 31, 2026 and December 31, 2027. After this award, Reddy beneficially owned 70,926 stock options directly.